At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
lapatinibdrug
Likely dose
lapatinib 1500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Clinical Study of Lapatinib (GW572016) in Patients With ErbB2 Over - Expressing Advanced or Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating lapatinib for Neoplasms, Breast. Completed, enrolled 62 participants across 9 sites.
Detailed Summary
This study (EGF104911) is designed to evaluate the efficacy and safety of lapatinib in patients with advanced or metastatic breast cancer. Eligible subjects must have ErbB2 overexpressing tumors and are refractory to treatment with anthracycline, taxanes and trastuzumab containing regimens. The study data obtained from EGF104911 will be combined with the data from EGF100642 and integrated analysis will be carried out in order to enhance the credibility of the study results.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Breast
Countries, Japan
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedMay 2006
Primary CompletionApr 2009
TodayJul 2026
First PostedMay 3, 2006
Enrollment StartNov 28, 2005
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.2 years ago
Interventions
lapatinibdrug
Lapatinib 1500mg QD